
Intelligent Bio Solutions Inc. (NASDAQ:INBS) on Wednesday announced the collection of new data that further reinforces the security and performance of its Intelligent Fingerprinting Drug Screening System, strengthening its FDA 510(k) submission.
"We are planning to submit our findings to the FDA in August, along with the new data collected," said Peter Passaris, Vice President of Product Development.